Clinical case of long-term surgical treatment of a patient with progression of renal cell carcinoma

Vladimir S. Chaykov , Elizaveta O. Shchukina , Ivan O. Dementev , Vitaly A. Biryukov , Ruiz Ninõ de Guzmán Roberto , Oleg B. Karyakin

For citation:

Abstract

Renal cell carcinoma is one of the most common malignant neoplasms of the genitourinary system. Disease progression occurs in 30% of patients after radical surgical treatment. Disease progression with metastatic spread to the contralateral kidney is quite rare (in 1–2% of cases). In such cases, differential diagnostics of disease progression with primary multiple malignant neoplasms of the kidneys is relevant. This is necessary to determine the correct treatment for patients.
Keywords: renal cell carcinoma, renal cell carcinoma progression, metastatic spread to the contralateral kidney, primary multiple cancer.

References

1. Global Cancer Observatory 2022. URL: https://gco.iarc.fr/en

2. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна и др. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. ISBN 978-5-85502-298-8

Malignant neoplasms in Russia in 2023 (morbidity and mortality). Ed. A.D. Kaprin et al. Moscow: Herzen Moscow Oncology Research Institute – branch of National Medical Research Center for Radiology, 2024. ISBN 978-5-85502-298-8 (in Russian).

3. Чайков В.С., Дементьев И.О., Карякин О.Б. и др. Ретроперитонеоскопический доступ при органосохраняющем лечении почечно-клеточного рака. Онкоурология. 2023;19(1):25-34. DOI: 10.17650/1726-9776-2023-19-1-25-34

Chaikov V.S., Dementiev I.O., Karyakin O.B. et al. Retroperitoneoscopic access in organ-preserving treatment of renal cell carcinoma. Oncourology. 2023;19(1):25-34. DOI: 10.17650/1726-9776-2023-19-1-25-34 (in Russian).

4. Базаев В.В., Дутов В.В., Еян П.А., Казанцева И.А. Инцидентальный почечно-клеточный рак: клинико-морфологические особенности. Урология. 2013;(2):66-9.

Bazaev V.V., Dutov V.V., Yeyan P.A., Kazantseva I.A. Incident renal cell carcinoma: clinical and morphological features. Urology. 2013;(2):66-9 (in Russian).

5. Beisland C, Guðbrandsdottir G, Reisæter LA et al. Aprospectiverisk-stratified followupprogramme for radically treated renal cell carcinoma patients: evaluation after eight 90 years of clinical use. World J Urol 2016;34(8):1087-99.

6. Пикин О.В., Алексеев Б.Я., Амиралиев А.М. Факторы прогноза хирургического лечения больных с метастазами рака почки в легких. Российский онкологический журнал. 2012;(3).

Pikin O.V., Alekseev B.Ya., Amiraliev A.M. Prognostic factors of surgical treatment of patients with metastases of kidney cancer in the lungs. Russian Journal of Oncology. 2012;(3) (in Russian).

7. Tosco L, Van Poppel H, Frea B et al. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol 2013;63(4):646-52. DOI: 10.1016/j.eururo.2012.09.037

8. Амиралиев А.М. Лечение больных с метастазами рака почки в легких. Диссертация канд. мед. наук. М., 2011.

Amiraliev A.M. Treatment of patients with metastases of kidney cancer in the lungs. Dissertation of the Candidate of Medical Sciences. Moscow, 2011 (in Russian).

9. Семков А.С., Махсон А.Н., Петерсон С.Б., Широкорад В.И. Хирургическое лечение костных метастазов рака почки. Онкоурология. 2010;(4):10-5.

Semkov A.S., Makhson A.N., Peterson S.B., Shirokorad V.I. Surgical treatment of bone metastases of kidney cancer. Oncourology. 2010;(4):10-5 (in Russian).

10. Кострицкий С.В., Широкорад В.И., Семенов Д.В. и др. Хирургическое лечение больных с метастазами рака почки в позвоночник. Онкоурология. 2014(3):40.

Kostritsky S.V., Shirokorad V.I., Semenov D.V. et al. Surgical treatment of patients with kidney cancer metastases in the spine. Oncourology. 2014(3):40 (in Russian).

11. Bianchi M, Sun M, Jeldres C, Shariat SF et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23(4):973-80. DOI: 10.1093/annonc/mdr362

12. Eggener SE, Yossepowitch O, Pettus JA. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006;24(19):3101-6.

13. Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000;164(2):322-25. DOI: 10.1016/s0022-5347(05)67350-8

14. Margulis V, McDonald M, Tamboli P et al. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 2009;181(5):2044-2051. DOI: 10.1016/j.juro.2009.01.043

15. ÖmerAcar, ÖnerŞanlı. Surgical Management of Local Recurrences of Renal Cell Carcinoma. Surgery Research and Practice 2016;2016:2394942. DOI: 10.1155/2016/2394942

16. Featherstone JM, Bass P, Cumming J, Smart CJ. Solitary, late metastatic recurrence of renal cell carcinoma: two extraordinary cases. Int J Urol 2006;13(12):1525-7. DOI: 10.1111/j.1442-2042.2006. 01577.x

17. Tapper H, Klein H, Rubenstein W et al. Recurrent renal cell carcinoma after 45 years. Clinical Imaging 1997;21(4):273-5. DOI: 10.1016/S0899-7071(96)00042-3

18. Novick AC, Streem S, Montie JE et al. Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol 1989;141(4):835-9. PMID: 2926874.

19. Lapini A, Serni S, Minervini А et al. Progression and long-term survival after simple enucleation for the elective treatmentof renal cell carcinoma: experience in 107 patients. J Urol 2005;174(1):57-60. DOI: 10.1097/01.ju.0000162019.45820.53. PMID: 15947577.

20. Serni S, Vittori G, Frizzi J et al. Simple enucleation for the treatment of highly complex renal tumors: Perioperative, functional and oncological results. Eur J Surg Oncol 2015;41(7):934-40. DOI: 10.1016/j.ejso. 2015.02.019. PMID: 25957967.

21. Wood EL, Adibi M, Qiao W et al. Local tumor bed recurrence following partial nephrectomy in patients with small renal masses. J Urol 2017;PII:S0022–5347(17)77555–6. DOI: 10.1016/j.juro.2017.09.072. PMID: 28941919.

22. Bani-Hani A.H et al. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J Urol 2005;173:391.

23. Степанова Ю.А., Калинин Д.В., Вишневский В.А. Первично-множественные опухоли (обзор литературы). Медицинская визуализация. 2015;(6):93-102.

Stepanova Yu.A., Kalinin D.V., Vishnevsky V.A. Primary multiple tumors (literature review). Medical imaging. 2015;(6):93-102 (in Russian).

24. Первично-множественные злокачественные опухоли. Руководство для врачей. Под ред. В.И. Чиссова, А.X. Трахтенберга. М.: Медицина, 2000.

Primary-multiple malignant tumors. A guide for doctors. Edited by V.I. Chissov, A.X. Trachtenberg. Moscow: Medicine, 2000 (in Russian).

25. Dabestani S, Marconi L, Hofmann F et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 2014;15(12):e549–61. DOI: 10.1016/s1470-2045(14)70235-9

26. Hang Lin, Heng Zhang, Yuanda Cheng, Chunfang Zhang. Solitary Metastasis in the Mediastinal Lymph Node After Radical Nephrectomy for Clear Cell Renal Cell Carcinoma: A Case Report and Literature Review. Case Reports Front Oncol 2020;10:593142. DOI: 10.3389/fonc.2020. 593142.eCollection 2020

27. NCCN Guidelines. NCCN Guidelines Version 1.2022.

28. Dudani Sh, de Velasco G, Wells JC et al. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Netw Open 2021;4(1):e2021869. DOI: 10.1001/jamanetworkopen.2020.21869

29. Matuszczak M, Kiljańczyk A, Salagierski M. Surgical Approach in Metastatic Renal Cell Carcinoma: A Literature Review. Cancers 2023;15:1804. DOI: 10.3390/cancers15061804

30. Ouzaid I, Capitanio U, Staehler M et al. Surgical Metastasectomy in Renal Cell Carcinoma: ASystematic Review. Eur Urol Oncol 2018;2:141-9.

31. Amiraliev A, Pikin O, Alekseev BY, Kalpinksiy A. Treatment strategy in patients with pulmonary metastases of renal cell cancer. Interact. CardioVasc Thorac Surg 2012;15:SXIII-F068.

32. Procházková K, Vodička J, Fichtl J et al. Outcomes for Patients after Resection of Pulmonary Metastases from Clear Cell Renal Cell Carcinoma: 18 Years of Experience. Urol Int 2019;103:297-302.

33. Meacci E, Nachira D, Congedo MT et al. Lung metastasectomy following kidney tumors: Outcomes and prognostic factors from a single-center experience. J Thorac Dis 2017; 9:S1267-S1272.

34. Pastorino U, Buyse, M, Friedel G et al. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases. J Thorac. Cardiovasc Surg 1997;113:37-49.

35. Ingels A, Campi R., Capitanio U et al. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 2022;19:391-418. DOI: 10.1038/s41585-022-00592-3

36. Коротаева А.А., Апанович Н.В., Брага Э.А. и др. Современные достижения в иммунотерапии рака почки. Онкоурология 2019; 15(4):30-8.

Korotaeva A.A., Apanovich N.V., Braga E.A. et al. Modern achievements in immunotherapy of kidney cancer. Oncourology 2019;15(4): 30-8 (in Russian).

37. Матвеев В.Б., Волкова М.И. Последовательная таргетная терапия при диссеминированном раке почки. Онкоурология. 2013;9(1):28-33.

Matveev V.B., Volkova M.I. Sequential targeted therapy for disseminated kidney cancer. Onkourologiya = Cancer Urology 2013;9(1):28-33 (in Russian).

38. Motzer RJ, Tannir NM, McDermott DF et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277-90. DOI: 10.1056/NEJMoa1712126

39. Cella D, Grünwald V, Escudier B et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treatedwithnivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol 2019;20(2):297-310. DOI: 10.1016/S1470-2045(18)30778-2

40. Sumanta Pal, Jun Gong, Shivani K Mhatre et al. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer 2019;19(1):548. DOI: 10.1186/s12885-019-5716-z

41. Kaprin AD, Ivanov SA, Klimenko AA, Dobrovolskaya NY. An example of the use of tyrosine kinase inhibitors as a targeted therapy for metastatic renal cell carcinoma. Malignanttumours 2015;1:49-52DOI: 10.18027/2224-5057-2015-1-49-52

42. Чубенко В.А. Осложнения таргетной терапии. Практическая онкология. 2010;11(3):192-202.

Chubenko V.A. Complications of targeted therapy. Practical oncology. 2010;11(3):192-202 (in Russian).

43. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711e23.

44. Reutova EV, Laktionov KP, Breder VV et al. Immune-mediatedadverse events associated with immune checkpoint inhibitors therapy. Malignant Tumours 2016;4:68-76

45. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373(2):123-35.

46. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373(17):1627-39.

47. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE–010): a randomizedcontrolled trial. Lancet 2016;387(10027):1540–50.

48. Topalian SL, Hodi FS, Brahmer J R et al. Safety, activity, and immune correlates of anti-PD–1 antibody in cancer. N Engl J Med 2012;366:2443e54.

49. Michot JM, Bigenwald C, Champiat S et al. Immunerelated adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54(1)39-48.

For citation:Chaykov V.S., Shchukina E.O., Dementev I.O., Biryukov V.A., Ruiz Ninõ de Guzmán Roberto, Karyakin O.B. Clinical case of long-term surgical treatment of a patient with progression of renal cell carcinoma. Clinical review for general practice. 2024; 5 (12): 18–25 (In Russ.). DOI: 10.47407/kr2024.5.12.00532

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice